Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers characterized the clinical features of ophiasis, an uncommon type of alopecia areata, and proposed a new subtype classification that may help predict treatment response and guide management, noting that ophiasis generally has a chronic and refractory nature.

This case report describes a patient with corticosteroid-resistant ophiasis alopecia areata who experienced prompt hair regrowth after receiving platelet-rich plasma injections.

This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.

In this case study, a 10-year-old girl with infantile ophiastic alopecia areata and ciliary madarosis showed excellent hair and eyelash regrowth after 56 days of treatment involving oral corticosteroids, topical minoxidil, and clobetasol hair lotion, following an initial diagnosis and psychological evaluation.

This case report describes a four-month-old infant with atypical alopecia areata following a cultural head-shaving ritual, who showed improvement with topical triamcinolone treatment, though not full symptom resolution, highlighting the rarity and complexity of managing AA in infants.

This study found that a combination treatment using oral and topical steroids with topical minoxidil was well-tolerated in children with severe recalcitrant alopecia areata, showing good responses except in alopecia universalis cases.

In this retrospective study, researchers observed that alopecia areata manifests in various forms among Malagasy children and presents challenges in treatment, with mixed regrowth results following corticosteroid therapy and methotrexate.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study reports that combination therapy with oral steroids, anthralin, and minoxidil yielded effective cosmetic responses in 80% of patients with treatment-resistant extensive alopecia areata.

This report describes five cases of bitemporal alopecia areata with frontal hairline involvement, detailing their management strategies and highlighting potential differential diagnoses, but does not present new clinical results.

This paper discusses alopecia areata, its autoimmune nature, factors influencing susceptibility, diagnostic challenges, and treatment limitations, concluding that no current therapy is curative or preventive; it reports no new clinical results.

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

In this study, trichoscopy consistently identified typical findings of frontal fibrosing alopecia, revealing three unusual clinical patterns in 18.4% of patients, which may aid in the differential diagnosis when clinical presentations are atypical.

This narrative review suggests that while corticosteroids and Janus kinase inhibitors may be effective for treating ophiasis-pattern alopecia areata in both adults and children, the limited age-specific evidence underscores the need for further research to confirm their efficacy and safety across age groups.

This study suggests that young females may experience a rare coexistence of Frontal Fibrosing Alopecia and ophiasis pattern Alopecia Areata, possibly sharing a common underlying pathophysiology.

The authors concluded that alopecia areata incognita, mainly affecting young females, generally has a more favorable prognosis than other types of alopecia areata.

A man had an unusual type of hair loss that didn't match known patterns and didn't improve with treatment.

This study found that 1% topical minoxidil induced significant hair regrowth in patients with alopecia areata, though it was less effective for those with extensive hair loss such as alopecia totalis and universalis.

In this study, topical tacrolimus 0.03% cream showed good to excellent response in treating alopecia areata in 70% of participants, with no cutaneous or systemic side effects observed.

This report discusses the potential of minoxidil for treating hair loss, spurred by early findings of hair regrowth in some patients, but emphasizes the need for further research to establish its safety and efficacy.

In this study, topical calcipotriol was found to be more effective than oral vitamin D for improving mild to moderate alopecia areata, with a 68% improvement rate and no correlation between serum vitamin D levels and treatment efficacy.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.

This report describes a case of a woman with ophiasis-pattern alopecia areata who experienced significant hair regrowth and maintained it for 6 months after treatment with dupilumab, though she eventually relapsed.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

Minoxidil promotes hair regrowth, but more research needed for effectiveness and response factors.

This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.

This study found that PRP was effective for treating alopecia areata with similar improvement across groups, while topical delivery via fractional CO2 laser or microneedling reduced injection pain.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.